Kathleen Mulligan, PhD

CTSI Profile Photo

Kathleen Mulligan, PhD

User Profile Name
Professor, School of Medicine
CTSI Profile Title
User Profile Email

Biography

I study the nutritional and metabolic effects of chronic conditions including HIV infection and its therapies, obesity, fatty liver disease, and type 2 diabetes, with a focus on body composition, glucose and lipid metabolism, endocrine function, and bone metabolism; and a strong emphasis on treatments and mechanisms. My research has ranged from leading intense inpatient metabolic ward studies to chairing multicenter trials through consortia such as the adult and pediatric AIDS Clinical Trials Groups and Adolescent Trials Network.
CTSI Profile Bio

Displaying 76 - 100 of 100

  1. Mulligan K, Zackin R, Von Roenn JH, Chesney MA, Egorin MJ, Sattler FR, Benson CA, Liu T, Umbleja T, Shriver S, Auchus RJ, Schambelan M, ACTG 313 Study Team . Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Endocrinol Metab. 2007 Feb; 92(2):563-70.
  2. Wohl DA, McComsey G, Tebas P, Brown TT, Glesby MJ, Reeds D, Shikuma C, Mulligan K, Dube M, Wininger D, Huang J, Revuelta M, Currier J, Swindells S, Fichtenbaum C, Basar M, Tungsiripat M, Meyer W, Weihe J, Wanke C. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis. 2006 Sep 01; 43(5):645-53.
  3. Lee GA, Lo JC, Aweeka F, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis. 2006 Sep 01; 43(5):658-60.
  4. Mulligan K, Parker RA, Komarow L, Grinspoon SK, Tebas P, Robbins GK, Roubenoff R, Dubé MP. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. . 2006 Apr 15; 41(5):590-7.
  5. Dubé MP, Parker RA, Tebas P, Grinspoon SK, Zackin RA, Robbins GK, Roubenoff R, Shafer RW, Wininger DA, Meyer WA, Snyder SW, Mulligan K. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS. 2005 Nov 04; 19(16):1807-18.
  6. Lo JC, Kazemi MR, Hsue PY, Martin JN, Deeks SG, Schambelan M, Mulligan K. The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clin Infect Dis. 2005 Nov 01; 41(9):1335-40.
  7. Danoff A, Shi Q, Justman J, Mulligan K, Hessol N, Robison E, Lu D, Williams T, Wichienkuer P, Anastos K, Women's Interagency HIV Study (WIHS) . Oral glucose tolerance and insulin sensitivity are unaffected by HIV infection or antiretroviral therapy in overweight women. . 2005 May 01; 39(1):55-62.
  8. Mulligan K, Zackin R, Clark RA, Alston-Smith B, Liu T, Sattler FR, Delvers TB, Currier JS, AIDS Clinical Trials Group 329 Study Team , National Institute of Allergy and Infectious Diseases Adult AIDS Clinical Trials Group . Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. Arch Intern Med. 2005 Mar 14; 165(5):578-85.
  9. Mulligan K, Anastos K, Justman J, Freeman R, Wichienkuer P, Robison E, Hessol NA. Fat distribution in HIV-infected women in the United States: DEXA substudy in the Women's Interagency HIV Study. . 2005 Jan 01; 38(1):18-22.
  10. Dubé MP, Kitch DW, Parker RA, Alston-Smith BL, Mulligan K. The effect of long-term storage on measured plasma lactate concentrations and prospective lactate results from a multicenter trial of antiretroviral therapy. Clin Chem Lab Med. 2005; 43(9):947-52.
  11. Shikuma CM, Zackin R, Sattler F, Mildvan D, Nyangweso P, Alston B, Evans S, Mulligan K, AIDS Clinical Trial Group 892 Team . Changes in weight and lean body mass during highly active antiretroviral therapy. Clin Infect Dis. 2004 Oct 15; 39(8):1223-30.
  12. Schwarz JM, Lee GA, Park S, Noor MA, Lee J, Wen M, Lo JC, Mulligan K, Schambelan M, Grunfeld C. Indinavir increases glucose production in healthy HIV-negative men. AIDS. 2004 Sep 03; 18(13):1852-4.
  13. Lo JC, Mulligan K, Noor MA, Lee GA, Schwarz JM, Grunfeld C, Schambelan M. The effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot study. Clin Infect Dis. 2004 Sep 01; 39(5):732-5.
  14. Lee GA, Mafong DD, Noor MA, Lo JC, Mulligan K, Schwarz JM, Schambelan M, Grunfeld C. HIV protease inhibitors increase adiponectin levels in HIV-negative men. . 2004 May 01; 36(1):645-7.
  15. Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, Aweeka FT, Mulligan K, Schambelan M, Grunfeld C. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS. 2004 Mar 05; 18(4):641-9.
  16. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med. 2003 Aug 19; 139(4):258-66.
  17. Mulligan K. Metabolic abnormalities in patients with HIV infection. J Int Assoc Physicians AIDS Care (Chic). 2003 Apr-Jun; 2(2):66-74.
  18. Grinspoon S, Mulligan K, Department of Health and Human Services Working Group on the Prevention and Treatment of Wasting and . Weight loss and wasting in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003 Apr 01; 36(Suppl 2):S69-78.
  19. Schambelan M, Benson CA, Carr A, Currier JS, Dubé MP, Gerber JG, Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K, Powderly WG, Saag MS, International AIDS Society-USA . Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. . 2002 Nov 01; 31(3):257-75.
  20. Tai VW, Schambelan M, Algren H, Shayevich C, Mulligan K. Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting. Clin Infect Dis. 2002 Nov 15; 35(10):1258-62.
  21. Mulligan K, Schambelan M. Anabolic treatment with GH, IGF-I, or anabolic steroids in patients with HIV-associated wasting. Int J Cardiol. 2002 Sep; 85(1):151-9.
  22. Napolitano LA, Lo JC, Gotway MB, Mulligan K, Barbour JD, Schmidt D, Grant RM, Halvorsen RA, Schambelan M, McCune JM. Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS. 2002 May 24; 16(8):1103-11.
  23. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS. 2002 Mar 29; 16(5):F1-8.
  24. Schwarz JM, Mulligan K, Lee J, Lo JC, Wen M, Noor MA, Grunfeld C, Schambelan M. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab. 2002 Feb; 87(2):942.
  25. Clark RA, Mulligan K, Stamenovic E, Chang B, Watts H, Andersen J, Squires K, Benson C. Frequency of anovulation and early menopause among women enrolled in selected adult AIDS clinical trials group studies. J Infect Dis. 2001 Nov 15; 184(10):1325-7.